Echinacea purpurea · herb
Evidence tier: weak
Activates immune response and reduces cold duration and severity
Immune modulation is the claim, and it is better characterised in the laboratory than in people. Alkylamides, cichoric acid and arabinogalactan polysaccharides are the constituents credited with activating innate immune cells. The reason this matters clinically is not the benefit but the contraindication built on top of it: because the mechanism is immune stimulation, echinacea is conventionally withheld from people on immunosuppressants. That precaution is mechanistic reasoning, not a trial finding.
Weak, and this is the most heavily tested herb in the batch, which is what makes the verdict so damning. Cochrane's review 'Echinacea for preventing and treating the common cold' (CD000530) pooled 24 double blind trials in 4,631 participants across 33 comparisons against placebo, and concluded: 'Echinacea products have not here been shown to provide benefits for treating colds, although, it is possible there is a weak benefit from some Echinacea products: the results of individual prophylaxis trials consistently show positive (if non significant) trends, although potential effects are of questionable clinical relevance.' Read that carefully. For TREATING a cold, not shown to work, and only one of seven treatment trials beat placebo. For PREVENTING a cold, the trends point the right way but do not reach significance, and Cochrane itself calls the size of any effect clinically questionable. NCCIH lands in the same place in plainer words: 'Taking echinacea may slightly reduce your chances of catching a cold. It's still unclear whether echinacea can shorten the length of a cold.' The counterweight, stated fairly: EMA HMPC does grant WELL ESTABLISHED USE to the expressed juice of fresh Echinacea purpurea herb, taken orally, for short term prevention and treatment of the common cold, in adults and adolescents over 12, with a doctor consulted if symptoms exceed 10 days. That is a real clinical designation and echinacea has earned it where most herbs have not. But the regulator granting well established use and Cochrane finding no treatment benefit are both true, and the honest synthesis of 4,631 randomised participants is a weak, possibly zero, possibly preventive effect of doubtful practical size.
Preparation matters more than milligrams here. The only preparation with EMA well established use is the expressed juice of the fresh flowering herb of Echinacea purpurea, oral, adults and adolescents over 12 years, for short term use, with a doctor consulted if the cold lasts beyond 10 days. Supplement products in circulation use different species (E. purpurea, E. angustifolia, E. pallida), different plant parts (herb versus root) and different extraction methods, and Cochrane names exactly this heterogeneity as a reason the trial results cannot be pooled cleanly. A dose that is right for one product tells you nothing about another.
Most effective when started at first symptoms, within 24 hours of cold onset. Use for maximum 10 days per episode. Do not use as continuous daily supplement. Take a break of at least 2 weeks between courses to avoid immune system desensitisation.
Well tolerated in short term use (up to 8 to 10 weeks). Not for long term continuous use, intended for early stage acute use only. Contraindicated in autoimmune conditions (lupus, MS, rheumatoid arthritis) due to immune stimulation. Avoid in patients on immunosuppressants (cyclosporine, tacrolimus, corticosteroids), may counteract immunosuppressive therapy. Cross reactivity in ragweed and Asteraceae allergic individuals. Not for progressive systemic diseases or immunodeficiency.
Pregnancy: caution
Breastfeeding: caution
Active compounds: alkylamides, cichoric acid, echinacoside, arabinogalactans, polysaccharides
Remedies using Echinacea · Browse by body system · Check it against what you take
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.